The $3 Billion Leak: How New Tech is Turning Hospital Waste into Patient Cures

CARROLLTON, GA – June 12, 2026 – In the intricate logistics of modern healthcare, a quiet but costly inefficiency persists. Every year, U.S. hospitals discard an estimated $3 billion worth of perfectly viable medications. This isn't just a financial drain; it represents millions of missed opportunities to treat patients. Now, a strategic partnership in Georgia between Tanner Health and the tech platform InStockRx aims to plug this leak, not just by managing inventory, but by fundamentally rethinking the value of every single dose.

The Anatomy of a Wasted Dose

Within the walls of every hospital pharmacy lies a "structural gap”—a gray area where medications are no longer returnable to wholesalers for credit but are still months or even years away from their expiration date. This inventory, often referred to as being in a "dead zone," has historically been one of the largest and most accepted sources of waste. Industry analysts estimate that 2% to 3% of the nation's $115 billion hospital medication expenditure in 2023 fell into this category, representing a staggering $2.3 to $3.45 billion in lost value.

The problem, however, is far more profound than a line item on a balance sheet. "A wasted dose is a missed opportunity for a patient," said Ron Hartman, PharmD, MHA, FACHE, system director of pharmacy at Tanner Health, a five-hospital nonprofit system serving communities in west Georgia and east Alabama. This sentiment cuts to the core of a growing crisis. In an era defined by persistent drug shortages and escalating costs, the idea of discarding usable medicine is becoming ethically and operationally untenable.

Research paints a stark picture of the challenge. One study found that nearly a quarter of all medications distributed within a hospital setting were ultimately returned unused and wasted. This is driven by everything from changes in a patient's treatment plan to inefficient vial sizes that don't match clinical needs. The operational burden is also immense, with pharmacy staff spending countless hours on manual inventory checks and navigating complex disposal protocols, pulling them away from direct patient care.

From Idle Inventory to Active Care

The collaboration between Tanner Health and InStockRx offers a compelling vision for how technology can transform this systemic waste into a strategic asset. Instead of letting surplus drugs languish on a shelf in one facility until they become waste, the InStockRx platform creates enterprise-wide visibility, turning idle inventory into a shared, active resource.

The platform integrates directly with Tanner’s existing supply chain infrastructure and its automated dispensing cabinets (ADCs). Using AI-powered analytics, it automatically identifies medications that are approaching the "structural gap." Rather than flagging them for disposal, it presents them as opportunities on an exclusive peer-to-peer marketplace. A pharmacy within the Tanner system—or even another verified hospital in the InStockRx network—can then acquire these medications to meet an immediate patient need.

"Tanner is a leader because they recognize that stewardship is a clinical priority," noted Mac Dougherty, CEO of InStockRx. "Even if a system is 99% efficient, that 1% represents real patients. We built InStockRx because we believe that in a world of drug shortages and rising costs, ‘good enough’ isn't good enough when it comes to patient access.”

A critical component of this model is its rigorous adherence to security and compliance. The movement of pharmaceuticals is one of the most heavily regulated processes in any industry. The platform ensures full compliance with the Drug Supply Chain Security Act (DSCSA), which mandates complete track-and-trace capabilities for all prescription drugs. InStockRx provides full DSCSA T3 documentation—transaction information, history, and statements—for every transfer, ensuring the integrity of the clinical supply chain. As the only pharmacy-to-pharmacy marketplace with GS1 certification, it uses verified, standardized drug identification data, meeting the highest FDA traceability standards that became fully enforceable this year.

A New Blueprint for Healthcare Innovation

Perhaps the most significant aspect of this story is not just the technology itself, but the model of innovation it represents. The partnership was facilitated by Healthliant Ventures, Tanner Health's own innovation arm, created specifically to identify and nurture promising startups. This structure provides a powerful alternative to the traditionally slow and risk-averse procurement cycles common in large healthcare organizations.

By acting as a strategic partner, Tanner provides startups like InStockRx with a real-world clinical environment to validate and refine their products. This symbiotic relationship allows the health system to proactively solve its own operational challenges while helping to co-develop solutions that can be scaled across the industry. It’s a blueprint for how legacy institutions can become engines of innovation rather than obstacles to it.

For Tanner Health, the goal is clear. "Our team is already incredibly lean and efficient, but we refuse to accept the idea that any amount of waste is standard," Hartman explained. "If there is a patient in one of our facilities who needs a medication that is sitting idle in another, our job isn't done. With this platform, we are ensuring that every dose we purchase fulfills its intended purpose.”

Securing the Last Mile of the Medical Supply Chain

Viewed from a wider lens, the Tanner-InStockRx initiative is more than a local efficiency play; it's a vital experiment in building a more resilient national healthcare infrastructure. The persistent threat of drug shortages has exposed the fragility of global pharmaceutical supply chains. While much focus is placed on manufacturing and international logistics, billions of dollars in resources are being lost at the very last mile—within the hospital walls themselves.

By creating a fluid, data-driven market for surplus medications, this model effectively increases the available supply of critical drugs without producing a single new vial. It transforms waste into a buffer stock that can be deployed dynamically to mitigate shortages, reduce treatment delays, and ultimately improve patient outcomes. If this approach were adopted by health systems across the country, it could unlock a hidden reservoir of medical resources, strengthening the entire healthcare ecosystem from within. The strategic decision to treat medication inventory not as a sunk cost to be managed, but as a dynamic asset to be optimized, may prove to be one of the most impactful innovations in modern hospital operations.